Fintel reports that on June 30, 2023, Mizuho reiterated coverage of Terns Pharmaceuticals (NASDAQ:TERN) with a Buy recommendation.
Analyst Price Forecast Suggests 106.73% Upside
As of June 2, 2023, the average one-year price target for Terns Pharmaceuticals is 17.51. The forecasts range from a low of 11.11 to a high of $24.15. The average price target represents an increase of 106.73% from its latest reported closing price of 8.47.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Terns Pharmaceuticals is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -1.93.
What is the Fund Sentiment?
There are 138 funds or institutions reporting positions in Terns Pharmaceuticals. This is an increase of 29 owner(s) or 26.61% in the last quarter. Average portfolio weight of all funds dedicated to TERN is 0.39%, an increase of 8.56%. Total shares owned by institutions increased in the last three months by 8.02% to 54,145K shares. 
The put/call ratio of TERN is 0.31, indicating a bullish outlook.
What are Other Shareholders Doing?
Orbimed Advisors holds 7,619K shares representing 13.44% ownership of the company. No change in the last quarter.
Vivo Capital holds 6,658K shares representing 11.75% ownership of the company. No change in the last quarter.
VR Adviser holds 3,620K shares representing 6.39% ownership of the company. In it's prior filing, the firm reported owning 3,708K shares, representing a decrease of 2.44%. The firm increased its portfolio allocation in TERN by 31.59% over the last quarter.
Suvretta Capital Management holds 3,448K shares representing 6.08% ownership of the company. No change in the last quarter.
Driehaus Capital Management holds 2,470K shares representing 4.36% ownership of the company. In it's prior filing, the firm reported owning 2,294K shares, representing an increase of 7.09%. The firm increased its portfolio allocation in TERN by 17.85% over the last quarter.
Terns Pharmaceuticals Background Information
(This description is provided by the company.)
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients.
Key filings for this company:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
